Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Shubham Pant, Joon Oh Park, Wu-Chou Su, et al.
The Lancet. Oncology
|
August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
The Lancet. Oncology
|
August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schuler, Gopa Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Siamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
European Urology Open Science
|
April 8, 2024
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, et al.
Current Opinion in Urology
|
October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
Benjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
Erdafitinib in Patients with FGFR-altered Advanced or Metastatic Cholangiocarcinoma
Shubham Pant, Joon Oh Park, Wu-Chou Su, et al.
The Lancet. Oncology
|
August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
The Lancet. Oncology
|
August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schuler, Gopa Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Siamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
European Urology Open Science
|
April 8, 2024
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study
F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, et al.
Current Opinion in Urology
|
October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
Benjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
Page
of 2